Exploratory study of AVI-4065 injection to design therapeutic dosing for chronic active HCV patients
Latest Information Update: 17 Jul 2019
At a glance
- Drugs AVI 4065 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Sarepta Therapeutics
- 14 Apr 2008 Status changed from recruiting to discontinued. According to ClinicalTrials.gov, the study was terminated because of limited viral load reduction in patients with hepatitis C.
- 21 Oct 2005 New trial record.